Uri Weinberg serves as the Chief Innovation Officer at NovoCure Ltd., a global oncology company pioneering a novel therapy called Tumor Treating Fields (TTFields) for the treatment of solid tumor cancers. With a robust background in medical device development and innovation, Weinberg has been instrumental in advancing NovoCure's mission to extend survival in some of the most aggressive forms of cancer. Prior to joining NovoCure, Weinberg held various leadership positions in the medical technology sector, where he spearheaded the development and commercialization of cutting-edge medical devices. At NovoCure, Weinberg's role as Chief Innovation Officer involves overseeing the company's research and development efforts, as well as driving the innovation strategy to expand the application of TTFields therapy across different cancer types. Under his leadership, NovoCure has made significant strides in clinical trials and product development, resulting in the approval of TTFields therapy for the treatment of glioblastoma and malignant pleural mesothelioma. Weinberg's expertise in medical device innovation and his strategic vision have been crucial in positioning NovoCure as a leader in the field of oncology. Weinberg's achievements extend beyond his work at NovoCure. He is a recognized thought leader in the medical technology industry, frequently speaking at conferences and contributing to publications on topics related to innovation in healthcare. His commitment to advancing cancer treatment through technology has earned him numerous accolades and has solidified his reputation as a driving force in the field. Weinberg's leadership and dedication to improving patient outcomes continue to shape the future of oncology and medical device innovation at NovoCure.